Outcomes of rotigotine clinical trials: effects on motor and nonmotor symptoms of Parkinson's disease.
Rotigotine transdermal system is a nonergot, 24-hour dopamine agonist approved for the treatment of early and advanced Parkinson's disease (PD). Recent studies have demonstrated significant improvements with rotigotine in motor function in early PD and significant improvements in daily off-time and motor function in advanced PD. In addition to motor improvements, nonmotor symptoms have been shown to be improved with rotigotine in both early and advanced PD. Rotigotine has been shown in large, controlled studies to be safe and efficacious for the treatment of motor and some nonmotor symptoms of early and advanced PD.
Department of Neurology, University of Kansas Medical Center, 3599 Rainbow Boulevard, Kansas City, KS 66160, USA. Kelly.lyons@att.net
Kelly E
KE
Lyons
Rajesh
R
Pahwa
D000279:Administration, Cutaneous; D000818:Animals; D018491:Dopamine Agonists / Q000008:administration & dosage*; D006801:Humans; D015337:Multicenter Studies as Topic / Q000639:trends*; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D016032:Randomized Controlled Trials as Topic / Q000639:trends*; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage*; D013876:Thiophenes / Q000008:administration & dosage*; D016896:Treatment Outcome
D018491:Dopamine Agonists; D013764:Tetrahydronaphthalenes; D013876:Thiophenes; C047508:rotigotine
Clinical trials; Motor symptoms; Nonmotor symptoms; Parkinson's disease; Rotigotine